Podcasts about mundipharma

Everything you need to know about treatment intensification in mHSPC!! Doublet vs Triplet. Who should have radiotherapy? PSMA PET/CT conundrums, e-escalation, case discussions and more. Featuring GU Cast Hosts Declan Murphy and Renu Eapen, Medical Oncologist Ben Tran, Nuclear Medicine Physician Louise Emmett, and Radiation Oncologist Amy Hayden. Plus lots of interaction from our live audience around Australia.Watch the full webinar including presentations on our YouTube channelThis GU Cast Live Event was an interactive educational webinar supported by our Gold Partners, Mundipharma.Learning objectives: 1. Provide an overview of the landscape of mHSPC today, with a particular focus on intensification of therapy2. Provide an overview of the role of novel and conventional imaging in diagnosis of mHSPC, both synchronous and metachronous3. To better understand options for intensification of systemic therapy in mHSPC4. To better understand the role of radiotherapy in mHSPC

How often do you check PSA and testosterone in your patients on androgen deprivation therapy? Declan caught up with friend of the podcast Professor Axel Merseburger at a conference recently to chat about thsi under-appreciated topic. Don't get too distracted by fancy scans and genomic testing; but do make sure you know a bit about why it matters to get testosterone (and PSA) as low as possible. This is a Themed Podcast supported by our Gold Partners, Mundipharma. Even better on our YouTube channel

In this episode of RegRapPod, host Alan Booth hears from Issue Editors, and Regulatory Rapporter Editorial Board members, Vickie Goff and Harriet Edwards, to discuss the focus topic of this issue, the Asia-Pacific region.Vickie Goff is Head of Marketed Products and Regulatory, CMC, Mundipharma, UKHarriet Edwards is Associate Director, Regulatory Affairs, Boyd Consultants Ltd., UK----------------------------------------------------------------SHOW NOTES:Managing Editor of Regulatory Rapporteur Alan Booth presented this podcast and the producer was Daisy Edwards; both at TOPRA in London.If you would like to advertise on the RegRapPod, please contact Erik Smit at Erik@topra.orgFor any other queries, please contact Daisy at daisy@topra.org, or you can write to Alan Booth, managing editor, at alan@topra.orgS1 Ep 10

One of our most popular episodes in 2022 was "Patting the Hormone Therapy Shark" with author, surfer and prostate cancer survivor, Tim Baker. And a lot has happened in the 12 months since so we invited Tim back for a follow-up chat in this Themed Podcast supported by our GU Cast Gold Partners, Mundipharma. Tim's inspiring approach to managing the side-effects of androgen deprivation therapy are well worth knowing for anyone involved in advanced prostate cancer including clinicians (especially clinicians!), nurses and allied health care professionals, industry, and of course patients and their loved ones. Tim runs through his "MEDS" strategy in this podcast, and also chats about other options including creative writing, the topic of his ongoing PhD. Thanks to our friends at Mundipharma for their ongoing support for GU Cast through their Gold Partnership. Even better on our YouTube channelLinks:Tim's websitePrevious GU Cast episode 

In this episode of AI For Pharma Growth, Dr Andree Bates is joined by  Alan Kalton, Senior Vice President of sales for Aktana and GM of Aktana's European division & Olivier Aurand, IT Director at Mundipharma.     Aktana is the category creator and leader of intelligent engagement in the global life sciences industry and helps companies strengthen their relationships with healthcare providers to inspire better patient care.    Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas.   In the final part of this three-part series on Next Best Action, Alan and Olivier discuss Next Best Action implementation success in pharma. In most industries you can just look at the individual sales, but things are different in pharma. For a start, in most countries we don't have access to individual prescribing data, and even if you do have access to these records companies can be reluctant to use that due to challenges around data privacy.    In this episode you will learn: What are some of the benefits of Next Best Action What does an express action do to make the whole infrastructure more impactful How does one define success with the Next Best Action implementation   Schedule a 15 minute conversation with Aktana to discuss your commercial outreach goals and determine your readiness for an AI-driven omnichannel solution: https://www.aktana.com/request-a-demo/   Click to connect with Dr. Andree Bates for more information in this episode: https://eularis.com/   AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business.    This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.   As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses  her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.    This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.   Resources:  Dr. Andree Bates LinkedIn | Facebook | Twitter 

In this episode of AI For Pharma Growth, Dr Andree Bates is joined by  Alan Kalton, Senior Vice President of sales for Aktana and GM of Aktana's European division & Olivier Aurand, IT Director at Mundipharma.   Aktana is the category creator and leader of intelligent engagement in the global life sciences industry and helps companies strengthen their relationships with healthcare providers to inspire better patient care.    Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas.   In this second part of a three-part series, Alan and Olivier examine how to design Next Best Action for scale.    In this episode you will learn:  What to do to scale NBA to be useable on a global scale Why some markets struggle to implement NBA  Why Pharma companies need to work in a more agile way How to overcome the regulatory and compliance issues based around using NBA in Pharma Advice for Pharma Leaders to engage their organisation to design an NBA program at scale   Schedule a 15 minute conversation with Aktana to discuss your commercial outreach goals and determine your readiness for an AI-driven omnichannel solution: https://www.aktana.com/request-a-demo/   Click to connect with Dr. Andree Bates for more information in this episode: https://eularis.com/   AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business.    This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.   As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses  her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.    This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.   Resources:  Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode of AI For Pharma Growth, Dr Andree Bates is joined by  Alan Kalton, Senior Vice President of sales for Aktana and GM of Aktana's European division & Olivier Aurand, IT Director at Mundipharma.   Aktana is the leader of intelligent engagement in the global life sciences industry and helps companies strengthen their relationships with healthcare providers to inspire better patient care.    Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas.   Pharma companies are introducing artificial intelligence powered Next Best Action (NBA) to drive proactive business intelligence into commercial execution. Next Best Action, also called context marketing, identifies the needs of individual physicians at specific moments of engagements to assist in the organisation of creating the right personalised content in the right channels at the right time, for every individual physician in a meaningful way and in real time. This creates a strong customer experience, alongside essential support for both sales and marketing professionals, while simultaneously providing stronger business results.    Alan & Olivier discuss some of the challenges and opportunities associated with delivering Next Best Action at scale, and reference the importance of using artificial intelligence and machine learning as it advances in its use cases.    In this episode you will learn: What needs to be done to implement Next Best Action (NBA) into Pharma How to make good decisions when implementing NBA in pharma What behavioural changes need to be made to stimulate the use of NBA The strategies to use help speed up the implementation of NBA Why markets are resistant to NBA   Schedule a 15 minute conversation with Aktana to discuss your commercial outreach goals and determine your readiness for an AI-driven omnichannel solution: https://www.aktana.com/request-a-demo/   Click to connect with Dr. Andree Bates for more information in this episode: https://eularis.com/   AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business.    This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.   As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses  her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.    This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.   Resources: Dr. Andree Bates LinkedIn | Facebook | Twitter

Matti Hemmi is the Chief Paradigm Shifter and founding partner of inKNOWation, a consulting firm specialising in delivering coaching, consulting, and mentoring to pioneering CEOs and their teams, with offices in Madrid and London. He is the author of three books published in Spanish (“Towards A New Paradigm”, “The Alchemy Of Creativity” and “Do You Dare To Dream?”), the latter is based on his viral video under the same name, with more than 22 million views on YouTube in its Spanish version. Over the last 15 years, they have worked with 11 of Spain's top 35 companies and numerous multinationals across Europe like Alphabet, Axel Springer, Beiersdorf, Bovis Lend Lease, Carrefour, GSK, Holcim, Johnson & Johnson, Kellogg's, Mercedes-Benz, Mundipharma, Nokia, Roche, Sage, Sandoz, Valeo, Viacom, Vodafone, Warner, and Wolters Kluwer. KEY TAKEAWAYS What is our attitude? The way we look at things will define how successful and contented we are with your relationships. If we look at everything from the perspective of “I am okay, you're okay” then our attitude will dictate how we see others and how they perceive us. When someone has an issue in their life and they are able to think this way it makes them more likely to find solutions because instead of focusing on what's wrong with them or why something happened; all that matters is finding ways for things "to be fixed. That's the only attitude out of four that really helps you produce the best result. BEST MOMENTS “As I started to realize were our success, late in business very often came to a point where a success was the consequence of having challenged the paradigm of the customer. So teaching them how to shift the way they were thinking.” “If you're feeling an emotion, you know, like an unpleasant emotion is not a problem, it only means that you are vibrating as we call it in a lower level of consciousness. That means when we perceive something is we call it negative, or in fact, is unpleasant. It only means our reading only half of the information that that reality is providing us. There's a principle we have in our frame of reference, which is called practice. And there are these eight different letters, each one is a principle. The second principle is called reality or for reality.” “Normally, we talk about positive and negative attitude. It's not a bad approach. But it I would say is a little bit simplistic, because it's, it doesn't give you enough details about what we're talking about. The model that we use is based on transactional analysis back from the 1960s for America. And he used to talk about the existential position. So how do we stand in life? And how do we see ourselves and how do we see the world and he came up with this model where there are four possibilities for attitude. And the most interesting one, and what we call the protagonist attitude is I'm okay, you're okay, which is I accept myself, I accept you unconditionally, even though I don't need to share what you think feel, or do. And this is really a very interesting concept.” ABOUT THE HOST Sıla Erol started her journey at TTC wetranslate Ltd as a Project Coordinator and has been continuing as a Key Account Manager after graduating from Translation and Interpreting Department at Ege University in Izmir/Turkey. CONTACT METHOD https://www.linkedin.com/in/sılaerol https://ttcwetranslate.com/ ABOUT THE GUEST Matti Hemmi is the Chief Paradigm Shifter and founding partner of inKNOWation. He is the author of three books published in Spanish. CONTACT METHOD https://www.linkedin.com/in/mattihemmi/ https://www.instagram.com/MattiHemmi/ https://www.facebook.com/HemmiMatti/ https://www.youtube.com/user/inKNOWation/ https://twitter.com/matti_hemmi VALUABLE RESOURCES Do you have any questions about translation, localization, or international growth? Visit TTC website: https://ttcwetranslate.com/ Are you curious about how ready you are to go global? Take TTC wetranslate's Scorecard: https://global.scoreapp.com/ Take your business global with the 5-step LINGO modal! Purchase 'Good Business in any Language' on Amazon now: https://cutt.ly/2ORR

A federal judge overturned Purdue Pharma's bankruptcy settlement which offered the Sackler family immunity from future civil liability. Purdue Pharma's $4.5 billion settlement would have funded treatment programs for opioid use disorder. This hour, Connecticut Attorney General William Tong discusses the state's successful appeal to reject the bankruptcy settlement and the continued push for accountability from the Sacklers. He's joined by corporate law professor, Joshua Silverstein, an expert in bankruptcy proceedings. Acute care nurse practitioner Stephen P. Wood, a Visiting Researcher at Harvard Law School, traces the history of Purdue Pharma and the Sacklers, a drug dubbed ‘Mother's Little Helper,' and the overseas sales of opioids by Purdue Pharma subsidiary Mundipharma. Anthropologist Alexa Dietrich of Wagner College, a researcher on the role of corporations in society, discusses ethics and corporate governance. Produced by Sujata Srinivasan and Abe Levine Technical Producer Cat Pastor GUESTS: William Tong: Connecticut Attorney General Joshua Silverstein: Professor of Law, University of Arkansas, Little Rock Stephen P. Wood: Bioethicist, Acute Care Nurse Practitioner, Visiting Researcher at Harvard Law School Alexa Dietrich: Associate Professor of Anthropology, Wagner College Support the show: http://wnpr.org/donate See omnystudio.com/listener for privacy information.

Neste episódio eu recebi o Carlos Grzelak que há mais de 20 anos se dedica a indústria da saúde com passagens pela Lilly, Pfizer, Chiesi, Glenmark, Emcure e agora Mundipharma, uma empresa com sede em Londres e que no Brasil atua com Oftalmologia, Oncologia e Dor.Falamos sobre o atual momento da empresa e as expectativas dele para o Brasil e o futuro da Indústria da Saúde.#viaoral

Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee's move to Boston. Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis […]

Episode 27 of  "B2B Marketing Asia Podcast"Ian has 20+ years of experience in leadership roles in companies like Colgate-Palmolive Philippines & Russia, Coca-Cola, GSK, and most recently with Mundipharma as Country Manager.His passion is developing people and delivering successful business results whether in slow growth, fast growth, or turnaround setting.In his most recent role in Mundipharma, Ian and his team were able to dramatically turn the business around, with the Philippine company awarded as the best large affiliate in Mundipharma. Mundipharma Philippines was also named as one of the Best Companies to Work For in the Philippines by HR Asia magazine. ABOUT JOE ESCOBEDO:Joe conducts regular educational workshops and trainings and is available for speaking engagements on the topics of content strategy / marketing, social selling, personal branding and media relations.SUBSCRIBE to get practical marketing, sales, and branding tips.WebsiteFollow me on LinkedIn!

Antonino was born and raised in Italy and moved to Mexico in 2016 as Latin America BD and Marketing Director for Ferring Pharmaceuticals. In 2018, he joined Mundipharma also as LATAM BD Director and then assumed the role of General Manager in Argentina. During his tenure in the pharma industry, Antonino has covered all commercial positions, including general management, business development & licensing, alliance management, project and transition leadership, marketing and sales, market access, pricing & reimbursement. Antonino is the Founder of Audaces Iuvat, a consultancy BD and commercial firm based in Mexico. Audaces Iuvat is the ideal partner for small to medium pharmaceutical/biotech companies that want to face the vast and complex Latin American market and need local expertise. It provides support from the search, selection, and negotiation of a partnership, to alliance management and follow-up of the commercial activities. AUDACES IUVAT may also advise on market access and pricing & reimbursement dynamics.

On this episode we are joined by Mr. Ian Santos - nominated as one of the most inspiring Filipinos on LinkedIn this 2020. He's a trainer, writer, speaker, and leadership consultant with a diverse management experience with global organizations like Coca-Cola, GlaxoSmithKline, Colgate-Palmolive and Mundipharma. He talks about his leadership journey, managing in a different cultural setting, breaking through busyness and his thoughts on digitalization. Enjoy the episode. Cheers! --- Send in a voice message: https://anchor.fm/theinspiringleader/message Support this podcast: https://anchor.fm/theinspiringleader/support

As negative press continued to increase for Purdue Pharma and the opioid epidemic, their market in the US began to dwindle. Prescriptions for OxyContin fell more than 40% since 2010, equating to billions lost revenue. The company’s owners, the Sackler Family, started pursuing a new strategy. Go global through their international company Mundipharma, and put the pain killer that set off the US opioid crisis into medicine cabinets around the world.” On May 22 of this year, Congresswoman Katherine Clark and Congressman Hal Rodgers released a report titled, Corrupting Influence – Purdue and the World Health Organization. This report exposed the dangerous opioid manufacturer’s influence on the WHO, and the potential jeopardy they present to foreign nations and developing countries. Today, we’re joined by Guardian reporter and bestselling author of American Overdose, Chris McGreal, and Daily Caller Journalist, Evie Fordham. Together we discuss this report, its impact on the World Health Organization, and Purdue Pharma’s strategy to breach international markets at the cost of making opioid crisis a global epidemic. We’ll frame today’s episode by revisiting an interview from 2 years ago with LA Times Journalist, Harriett Ryan on an article she wrote titled “OxyContin goes global – We’re only just getting started”. Join us on today’s podcast for an in depth look at Purdue Pharma’s influence over the WHO and its attempts to spread OxyContin worldwide

Today in FirstWord:

Prostate, colorectal, lung and breast cancers are the top killers but they are also the ones with the highest survivor rates. How does one cope after a cancer diagnosis? Guests: Associate Professor Cynthia Ruth Goh-Fung, Council Member of the Singapore Hospice Council and Senior Consultant, Division of Supportive and Palliative Care at the National Cancer Centre Singapore; Raman Singh, CEO of Mundipharma; Dr Lim Siew Eng, Senior Consultant in the Department of Haematology-Oncology at the National University Cancer Institute in Singapore; and Noor Quek, President of the Breast Cancer Foundation in Singapore.

With the widespread use of technology, are healthcare professionals losing their human touch? Guests: Prof Tan Huay Cheem, Director of the National University Heart Centre, Singapore; Raman Singh, Chief Executive Officer of Mundipharma; Tin Pei Ling, Member of Parliament (Singapore), Member of the Government Parliamentary Committee – Health (Singapore); Ong Leong Seng, Director, Delivery Group, Integrated Health Information Systems (Singapore).

How does ASEAN fare compared to their western counterparts when it comes to innovative healthcare?  Guests: Dr Stephen Chan, Chief Medical Informatics Officer, Woodlands Health Campus (Singapore); Raman Singh, Chief Executive Officer of Mundipharma; Gillian Tee, Co-founder and Chief Executive Officer of Homage; Phua Tien Beng, Chief Executive Officer, Singapore Operations Division, Parkway Pantai.

Patients today are empowered with knowledge as healthcare information is readily available. How does one use that information to make the best decisions? Guests: Adj Asst Prof Tan Tze Lee, President of the College of Family Physicians (Singapore); Raman Singh, Chief Executive Officer of Mundipharma; Dr Wong Sweet Fun, Deputy Chairman, Medical Board and Senior Consultant, Geriatric Medicine, Khoo Teck Puat Hospital; Dr Lim Toon Wei, Senior Consultant, Department of Cardiology, National University Heart Centre, Singapore.

While the public sector in some countries struggles to provide for the people, the private sector remains an untapped reservoir of resource. How can public and private sectors collaborate for successful partnerships to provide quality healthcare ? Guests: Dr Chia Shi-Lu, Member of Parliament, Singapore, Chairperson, Government Parliamentary Committee, Health (Singapore); Raman Singh, Chief Executive Officer of Mundipharma; Peh Kim Choo, Chief Executive Officer of Tsao Foundation; Associate Professor Lim Yee Wei, Yong Loo Lin School of Medicine, National University of Singapore.

Over the past 10 years, the ASEAN region has tackled epidemics ranging from SARS to H5N1. With infectious diseases easily crossing borders, are we prepared for the next epidemic that may hit our shores? Guests: Dr Sebastian Maurer-Stroh, Senior Principal Investigator, Programme Director, Human Infectious Diseases at the Bioinformatics Institute, A*STAR Singapore; Raman Singh, Chief Executive Officer of Mundipharma; Prof Leo Yee-Sin, Clinical Director, Communicable Diseases Centre (Singapore), Executive Director, National Centre for Infectious Diseases, Ministry of Health (Singapore); and Assoc Prof Teoh Yee Leong, Chief Executive Officer, Singapore Clinical Research Institute.

Today in FirstWord:

Today in FirstWord: